Outlook Wealth Advisors LLC Makes New $355,000 Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Outlook Wealth Advisors LLC purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the fourth quarter, Holdings Channel.com reports. The firm purchased 7,428 shares of the biopharmaceutical company’s stock, valued at approximately $355,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at about $49,000. GAMMA Investing LLC grew its position in Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 350 shares in the last quarter. Toth Financial Advisory Corp bought a new stake in Halozyme Therapeutics in the third quarter worth $57,000. FSC Wealth Advisors LLC bought a new stake in Halozyme Therapeutics in the third quarter worth $65,000. Finally, Park Place Capital Corp increased its position in Halozyme Therapeutics by 828.1% during the third quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 1,209 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on HALO. Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Wells Fargo & Company cut their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday. HC Wainwright raised their target price on Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price target for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Finally, Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $60.89.

Halozyme Therapeutics Trading Up 1.6 %

HALO opened at $55.37 on Friday. The firm’s fifty day simple moving average is $49.75 and its 200 day simple moving average is $54.07. The stock has a market capitalization of $7.04 billion, a P/E ratio of 18.33, a P/E/G ratio of 0.40 and a beta of 1.24. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53.

Insider Activity at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now owns 43,611 shares in the company, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.40% of the stock is owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.